Filing search / Incannex Healthcare Limited / "Recruit"

8-K

EX-99.1

IXHL Incannex Healthcare Limited

24 Oct 24

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

7:30am

in the first half of 2025. The “PsiGAD2” Phase 2 trial is expected to recruit 94 patients with GAD, including those currently treated with selective

8-K

EX-99.1

IXHL Incannex Healthcare Limited

30 Sep 24

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

4:01pm

to recruit 560 subjects, with an estimated 355 participants in the active study arms, and anticipates reporting top-line data from the Phase 2 portion

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

population is individuals aged 18 years or older with OSA who are intolerant, non-compliant or naïve to positive airway pressure. We plan to recruit 560 … and efficacy data with respect to the drug candidate; our ability to recruit clinical trial investigators with the appropriate competencies and experience

8-K

EX-99.1

IXHL Incannex Healthcare Limited

5 Aug 24

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

8:15am

of the trial and prospective drug product. PsiGAD2 will recruit approximately 94 patients with generalised anxiety disorder, including those currently being

S-1/A

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

clinical trials depends on the speed at which we can recruit patients to participate in testing our drug candidates. Patients may be unwilling … also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. If healthcare insurers

S-1

vtol3

3 Jul 24

IPO registration

6:29am

8-K

EX-99.1

hcmvsn0eyrxc2 xn6sjd

30 May 24

Other Events

8:30am

8-K

EX-99.1

26ta f62l2

16 Apr 24

Incannex Healthcare Inc. Quarterly Update, Q1 2024

9:30am

6-K

EX-99.1

716msp z1r

1 Sep 23

Report of Foreign Private Issuer

12:00am

6-K

EX-99.1

7hdy4u346

15 Jun 23

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

9:06pm

20-F

7jyo51xywr9iz

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

oyr39l439

19 Sep 22

Report of Foreign Private Issuer

9:38pm

6-K

EX-99.1

tpoiza9 7jo

12 May 22

Report of Foreign Private Issuer

9:25am

20FR12B/A

w8zp0it87pgedica5q7

24 Feb 22

Initial registration of securities (foreign private issuers) (amended)

3:42pm

20FR12B/A

1csurfi sn5bq4zt4

22 Feb 22

Initial registration of securities (foreign private issuers) (amended)

6:10am

20FR12B

EX-4.4

fz5uoc

24 Jan 22

Initial registration of securities (foreign private issuers)

8:18pm

20FR12B

sl71rgi

24 Jan 22

Initial registration of securities (foreign private issuers)

8:18pm

20FR12B

EX-4.6

6c0laa2m0ep0r59yu4

24 Jan 22

Initial registration of securities (foreign private issuers)

8:18pm

20FR12B

EX-4.5

8m8m4z 0vy

24 Jan 22

Initial registration of securities (foreign private issuers)

8:18pm